How much is the vulvovaginal candidiasis treatment market worth, and how is it expected to expand?
The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing disease burden of vulvovaginal candidiasis disorder, increasing number of insurance facilities, increasing clinical trials, rising research and developmental activities, increasing usage of broad-spectrum antibiotics.
The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing healthcare spending, growing geriatric population, increasing prevalence of chronic diseases, growing development of new antifungal drugs, increasing awareness of vaginal disorders. Major trends in the forecast period include technological advancements, strategic collaboration, investment in research and development, advance treatment options, advanced therapies.
Get Your Free Sample of The Global Vulvovaginal Candidiasis Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21319&type=smp
Which industry factors have accelerated the vulvovaginal candidiasis treatment market’s expansion?
The rising awareness of vaginal disorders is expected to propel the growth of the vulvovaginal candidiasis treatment market going forward. Vaginal disorders refer to conditions affecting the vagina, including infections, inflammation, irritation, or abnormal discharge. Rising awareness of vaginal disorders is driven by increased education, improved access to healthcare, and a growing focus on women’s health and well-being. Vulvovaginal candidiasis treatment supports vaginal disorder patients by alleviating symptoms such as itching, irritation, and abnormal discharge, restoring the natural vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For instance, in October 2024, according to the Cancer Australia, an Australia-based government agency, an estimated 123 new cancer cases of vaginal cancer diagnosed in 2022, of which 30 people died of vaginal cancer. Therefore, the rising awareness of vaginal disorders is driving the growth of the vulvovaginal candidiasis treatment market.
What are the primary segments of the vulvovaginal candidiasis treatment market?
The vulvovaginal candidiasis treatment market covered in this report is segmented –
1) By Drug Class: Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous, Topical
3) By Distribution Channel: Hospital Pharmacy , Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Clotrimazole: Over-the-Counter (OTC) Medications, Prescription Medications
2) By Nystatin: Monotherapy, Combination Therapy
3) By Fluconazole: Single-Dose Therapy, Multi-Dose Therapy
4) By Ketoconazole: Short-Term Treatment, Long-Term Treatment
5) By Terbinafine: Systemic Treatment, Topical Treatment
6) By Terconazole: Low-Dose Therapy, High-Dose Therapy
7) By Other Drug Classes: Azole Antifungals, Polyene Antifungals, Novel Therapeutics
Order your report now for swift delivery
Which firms are leading the vulvovaginal candidiasis treatment market?
Major companies operating in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals
Which market trends are set to define the future of the vulvovaginal candidiasis treatment market?
Major companies operating in the vulvovaginal candidiasis treatment market are focusing on novel pharmaceuticals, such as an oral and non-azole medication, to enhance treatment effectiveness and patient convenience. Oral and non-azole medication refers to antifungal drugs taken orally that do not belong to the azole class, offering an alternative treatment for fungal infections. For instance, in December 2022, Scynexis Inc., a US-based biotechnology company, announced BREXAFEMME (ibrexafungerp tablets), an oral and non-azole medication, for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) approved by the Food and Drug Administration (FDA), a US-based government agency. BREXAFEMME is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. This approval positions BREXAFEMME as a key treatment option for patients with recurrent infections, offering a novel approach to managing RVVC.
Which geographic trends are shaping the vulvovaginal candidiasis treatment market, and which region has the highest market share?
North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in the vulvovaginal candidiasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Vulvovaginal Candidiasis Treatment Market Report 2025 Offer?
The vulvovaginal candidiasis treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Vulvovaginal candidiasis treatment refers to the medical management of a common fungal infection caused by candida species, affecting the vaginal area. The treatment aims to alleviate symptoms such as itching, burning, and abnormal discharge. The primary use of these treatments is to relieve discomfort, restore balance, and prevent recurrence of the infection.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21319
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
